SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q/A

 

Amendment No. 3

 

Quarterly Report under Section 13 or 15 (d) of

Securities Exchange Act of 1934

 

For Period ended December 31, 2012

 

Commission File Number 0-32201

 

BIO-MATRIX SCIENTIFIC GROUP, INC.

(Exact name of registrant as specified in its charter)

 

   
DELAWARE 33-0824714
(State of Incorporation) (I.R.S. Employer Identification No.)
   
4700 Spring Street, Suite 304, La Mesa, California 91942
(Address of Principal Executive Offices) (Zip Code)

 

(619) 702-1404

(Registrant's telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

   
☐  Large accelerated filer ☐  Accelerated filer
   
☐  Non-accelerated filer ☑  Smaller reporting company

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934) (check one): Yes ☐   No    ☑

 

There were : 1,998,299,049 shares of Common Stock outstanding as of June 13, 2013.

 

 

EXPLANATORY NOTE

 

THIS AMENDMENT NO. 3 TO BIO-MATRIX SCIENTIFIC GROUP, INC’S (THE “COMPANY”) FORM 10-Q FOR THE PERIOD ENDED DECEMBER 31, 2012 (“FORM 10-Q”) IS BEING FILED SOLELY TO AMEND THE FOLLOWING PORTIONS OF AMENDMENT NO. 2 TO THE FORM 10-Q (“ORIGINAL FILING”).

 

PART 1, ITEM 1 FINANCIAL STATEMENTS CONSOLIDATED STATEMENT OF CASH FLOW

 

THE COMPANY HAS NOT MODIFIED OR UPDATED DISCLOSURES PRESENTED IN THE ORIGINAL FILING, EXCEPT AS INDICATED ABOVE. ACCORDINGLY, THIS AMENDMENT DOES NOT REFLECT EVENTS OCCURRING AFTER THE DATE OF THE ORIGINAL FILING AND DOES NOT MODIFY OR UPDATE THOSE DISCLOSURES AFFECTED BY SUBSEQUENT EVENTS, EXCEPT AS SPECIFICALLY REFERENCED HEREIN. INFORMATION NOT AFFECTED BY THE ABOVE AMENDMENTS IS UNCHANGED AND REFLECTS THE DISCLOSURES MADE AT THE TIME OF THE ORIGIN

 

 

 
 

 

 

 

BIO-MATRIX SCIENTIFIC GROUP, INC.               
(A Development Stage Company)               
CONSOLIDATED STATEMENT OF CASH FLOWS               
                
                
                
                
    (unaudited)    (unaudited)    (unaudited) 
    Three Months Ended     Three Months Ended     From inception to 
    December 31, 2012    December 31, 2011     December 31, 2012 
               
CASH FLOWS FROM OPERATING ACTIVITIES               
                
Net Income (loss)  $(596,666)  $(213,673)  $25,950,645 
Adjustments to reconcile net Income to net cash               
(used in) provided by operating activities:               
Depreciation expense             2,667 
Stock issued for compensation to employees   26,400         1,253,551 
Stock issued for services rendered by consultants             4,223,130 
Stock issued for prepaid expenses             313,665 
Stock issued for interest   2,120         140,667 
Gain recognized on deconsolidation of Subsidiary             (42,000,000)
Changes in operating assets and liabilities:               
(Increase) decrease in prepaid expenses             (15,000)
Increase (Decrease) in Accounts Payable   4,505    1,750    137,545 
Increase (Decrease) in Accrued Expenses   115,110    89,777    695,576 
Increase (Decrease) in Due to Affiliate   (4,245)        34,895 
Equity in Loss of Entest        55,333    663,649 
Net Cash Provided by (Used in) Operating Activities   (452,776)   (66,813)  $(8,599,010)
                
CASH FLOWS FROM INVESTING ACTIVITIES               
(Increase) Decrease in Other Assets             (4,200)
Purchases of fixed assets             (541,536)
Disposal of Fixed Assets             7,300 
Loss on Disposal of Equipment             531,569 
Net Cash Provided by (Used in) Investing Activites             (6,867)
                
CASH FLOWS FROM FINANCING ACTIVITIES               
Preferred Stock issued for Cash             874,985 
Common Stock issued for Cash             621,164 
Common Stock issued for Accrued Salaries             424,500 
Common Stock issued pursuant to Contractual Obligations   35,223         101,595 
Additional paid in Capital   290,000    40,909    1,252,945 
Principal borrowings on Convertible Debentures   316,216    10,850    1,022,025 
Principal borrowings (repayments) on notes and Convertible Debentures   (263,600)   25,108    2,668,929 
Net Borrowings From Related Parties             1,195,196 
Contributed Capital             509,353 
Increase (Decrease) in Notes from Affiliated party             1,000 
(Increase) Decrease in Deferred Financing Costs             (65,000)
  Net Cash Provided by (Used in) Financing Activities   377,839    76,867    8,606,692 
                
Net Increase (Decrease) in Cash   (74,937)   10,054   $815 
                
Cash at Beginning of Period   75,752    331    0 
                
Cash at End of Period  $815   $10,385   $815 
                
Supplemental Disclosure of Noncash investing and financing activities:          
Common Shares Issued for Debt  $181,504        $1,883,037 
                
                
The Accompanying Notes are an Integral Part of These Financial Statements
                

 

 
 

EXHIBITS:

31.1 Certification of Chief Executive Officer
31.2 Certification of Acting Chief Financial Officer
32.1 Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

 

 
 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   
   
  Bio-Matrix Scientific Group, Inc.
  a Delaware corporation
   
By: /s/ David R. Koos
  David R. Koos
  Chief Executive Officer
   
  September 9, 2013